Legal & General Group PLC Glycomimetics Inc Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$2.16 - $3.18 $6,454 - $9,501	-2,988 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$3.07 - $5.0 $3,812 - $6,210	-1,242 Reduced 29.36%	2,988 $9,000
Q2 2020 Aug 14, 2020	SELL	$2.06 - $3.76 $2,694 - $4,918	-1,308 Reduced 23.62%	4,230 $16,000
Q1 2020 May 14, 2020	SELL	$1.83 - $5.41 $2,245 - $6,638	-1,227 Reduced 18.14%	5,538 $13,000
Q4 2019 Feb 13, 2020	BUY	$4.03 - $6.5 $2,603 - $4,199	646 Added 10.56%	6,765 $36,000

Q1 2019 May 15, 2019	BUY	$9.96 - $13.44 $4,452 - $6,007	447 Added 7.88%	6,119 $76,000
Q2 2018 Aug 10, 2018	BUY	$14.63 - $19.19 $82,981 - $108,845	5,672 New	5,672 $92,000

36.8M

969K

636K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.7M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.